Artios Pharma secured a $115 million oversubscribed Series D to accelerate its DDR cancer pipeline, including alnodesertib and ART6043.

The round was led by SV Health Investors with new investor RA Capital Management and participation from Janus Henderson Investors, alongside existing backers.

Artios plans a Phase 2 randomized trial of ART6043, a Pol? inhibitor, in BRCA-mutant, HER2-negative breast cancer patients eligible for PARP inhibitors, following encouraging Phase 1/2a data presented at ESMO and September 2025 data.

SV Health Investors signaled long-term support for Artios’ late-stage development and growth, reflecting confidence in the company’s trajectory.

IP Group’s Greg Smith highlighted Artios as a prime example of UK life sciences strength with real commercial promise.

The article notes a cautionary disclaimer about investment advice and cryptocurrency volatility, framing it as marketing context.

Since August, Michael Andriole is CEO, succeeding founder Niall Martin; Andriole is steering late-stage development and commercialization.

Artios CEO Andriole and investors from SV Health and RA Capital stressed advancing late-stage development and building a commercially oriented company.

Industry observers from SV Health and RA Capital underscored Artios’ differentiated DDR pipeline and potential for first-in-class therapies in DDR.

Artios focuses on exploiting DDR pathways, with emphasis on ATM-deficient tumors where alnodesertib has shown durable responses across eight solid tumor types.

Andriole warned that the Series D accelerates registration pathways for alnodesertib and ART6043 and broadens DDR development for high-need cancers.

Executives and investors noted the milestone would accelerate regulatory pathways and expand DDR development in pancreatic, colorectal, and breast cancers with high unmet need.